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New strategies are required to identify the most important tar-
gets of protective immunity in complex eukaryotic pathogens.
Natural selection maintains allelic variation in some antigens of
the malaria parasite Plasmodium falciparum1–3. Analysis of allele
frequency distributions could identify the loci under most in-
tense selection4–7. The merozoite surface protein 1 (Msp1) is the
most-abundant surface component on the erythrocyte-invad-
ing stage of P. falciparum8–10. Immunization with whole Msp1
has protected monkeys completely against homologous11 and
partially against non-homologous12 parasite strains. The single-
copy msp1 gene, of about 5 kilobases, has highly divergent alle-
les13 with stable frequencies in endemic populations14,15. To
identify the region of msp1 under strongest selection to main-
tain alleles within populations, we studied multiple intragenic
sequence loci in populations in different regions of Africa and
Southeast Asia. On both continents, the locus with the lowest
inter-population variance in allele frequencies was block 2, indi-
cating selection in this part of the gene. To test the hypothesis
of immune selection, we undertook a large prospective longitu-
dinal cohort study. This demonstrated that serum IgG antibod-
ies against each of the two most frequent allelic types of block 2
of the protein were strongly associated with protection from P.
falciparum malaria.
We first determined allele frequency distributions throughout
the merozoite surface protein 1 (msp1) gene by genotyping ten
loci spanning the gene in 547 Plasmodium falciparum isolates
from six populations in Africa (located in The Gambia, Nigeria,
Gabon, Sudan, Tanzania and South Africa), using PCR amplifica-
tion followed by allele sequence-specific oligonucleotide prob-
ing16. We determined the allele frequencies at each of the msp1
intragenic loci in each population, together with the inter-popu-
lation component of variance in allele frequencies (Wright’s FST)
(ref. 17) (Table 1). As recombination was frequent (linkage dise-
quilibrium is generally less than half its maximal value over dis-
tances of more than 0.3 kilobases in most of the populations)16,
the loci had mostly independent allele frequency distributions.
We sought the locus with the lowest FST value (that is, with the
lowest inter-population divergence and the highest proportion
of overall allelic diversity maintained within each population) as
that under strongest selection to maintain alleles6,7. Nine of the
loci had FST values that differed significantly from zero, indicat-
ing heterogeneity in allele frequencies among populations. In
contrast, the block 2 locus showed a non-significant value near
zero (FST = 0.008), so almost all of the diversity at this locus ex-
isted within each population.
To determine the typical range of genetic variance among
these P. falciparum populations at non-antigen loci for which
there is no hypothesis of selection, we genotyped nine mi-
crosatellite tri-nucleotide TAA(n) repeat loci (ta1, ta42, ta81,
ta87, ta109, PfPK2, G377, Polya and ARA2)18,19 each in more than
50 isolates from each of the six populations. We discriminated
alleles by size of products amplified by PCR (ref.19), with an ob-
served number of distinct alleles per locus ranging from 7 (locus
G377) to 22 (locus ta1). Overall, the microsatellite loci showed
moderate inter-population variance in allele frequencies (mean
FST value = 0.026), higher than that for block 2 of msp1. For all ex-
cept one (G377) of these nine loci individually, the FST values ex-
ceeded that of block 2 and were highly significantly above zero (P
< 0.01 for locus ARA2; P < 0.001 for each of the other seven loci).
Thus, the block 2 locus in msp1 has a lower FST value than most
putatively neutral loci.
In a separate study, we also determined whether block 2 had an
unusually low inter-population variance in allele frequencies in
another continent. We genotyped block 2 and three other poly-
morphic loci in the msp1 gene in an overall sample of 655 alleles
from two populations in Southeast Asia (located in Thailand and
Vietnam), using a method of nested PCR with allele sequence-
specific internal primers15,20. We determined the allele frequen-
cies in each population, with FST indices (Table 2). Whereas the
other loci have FST values significantly different from zero, the
value for block 2 was again non-significant and almost zero.
Thus, results of African and Southeast Asian studies indicate that
block 2 is the region of the msp1 gene under the strongest selec-
tion to maintain alleles in both continents.
Block 2 sequences of msp1 belong to one or another of three
highly divergent allelic types: K1-like, MAD-like and RO33-like.
The K1-like and MAD-like types encode protein segments in the
size ranges of 47–89 amino acids or 35–59 amino acids, respec-
tively (each type incorporates many different subtypes that dif-
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fer in sequence and length
of tri-peptide repeats in the
middle of the block,
flanked by non-repetitive
sequences that are highly
conserved within each type
but that differ between
types). A mouse mono-
clonal antibody against the
K1-like repeats inhibits P.
falciparum growth in vitro21.
The RO33-like type encodes
a sequence of 46 amino
acids without repeats and
with little subtypic varia-
tion22. Recombinant pro-
teins have been expressed
in Escherichia coli, repre-
senting examples of sub-
types from each of the
three main allelic types of
block 2 (refs. 23,24). Type-
specific epitopes on these
block 2 proteins are com-
monly recognized by anti-
bodies induced during
natural P. falciparum infec-
tions, and antibodies
against subtype-specific epitopes are detected occasionally24,
but no naturally acquired human antibodies cross-react among
the three types of block 2 (refs. 23,24).
To determine whether type-specific human antibodies
against block 2 of Msp1 are protective against P. falciparum
malaria, as the population genetic study would predict, we un-
dertook a prospective longitudinal cohort study in The
Gambia. In June 1996, immediately before the annual malaria
transmission season, we collected sera from 337 children (3–7
years of age), to be tested later for antibody reactivity with re-
combinant antigens representing different allelic forms of
block 2, or other blocks of the Msp1 protein. We monitored
these children for five months (July to November), with active
and passive case detection of  malaria.
We determined the proportions of individuals who experi-
enced clinical malaria at any time during the five months,
among those with or without detectable serum IgG levels
against particular Msp1 recombinant antigens at the start of
the study (Table 3). Consistent with the deduced hypothesis,
the presence of serum IgG against either of the two most com-
mon block 2 types, K1-like and MAD-like (with allele frequen-
cies in The Gambia of 0.51 and 0.33, respectively; Table 1) was
highly significantly and independently associated with a lower
prospective risk of malaria. The relative risks (0.64–0.67 for IgG
against the K1-like type, and 0.54–0.78 for IgG against the
MAD-like type) gave protective efficacy estimates (1–relative
risk) in the range of 22–46%. These effects remained statisti-
cally significant for five of the seven K1-like or MAD-like sub-
types tested, after controlling for individuals’ ages in years.
Logistic regression analysis of relative antibody levels (ab-
sorbance levels) gave similar results to those for antibody posi-
tivity against antigens representing the K1-like and MAD-like
types of block 2; that is, higher absorbance values were signifi-
cantly associated with protection from clinical malaria (P <
0.05 for each of the seven recombinant antigens representing
these block 2 types).
The highly significant protective efficacy estimates of
22–46% for antibodies against either of the common K1-like or
MAD-like block 2 types were not dissimilar to the maximum
possible for type-specific immunity (given that the frequencies
of these main allelic types of block 2 in the Gambia were 0.51
and 0.33). If block 2 type-specific antibodies protect in a para-
site allele-specific manner, their effects should be additive,
and individuals with antibodies against both of the common
block 2 types (K1-like and MAD-like) should be very well pro-
tected. This was indeed the case. Only 7 (21.2%) of the 33 in-
dividuals who had antibodies against representative antigens
of both types (3D7 antigen of the K1-like type, and Wellcome
antigen of the MAD-like type) subsequently had malaria, com-
Table 1 Allele frequencies in six African populations and FST indices of inter-population variance at ten
polymorphic loci within the msp1 gene of P. falciparum
Population allele frequencies
Locus Allele Gambia Nigeria Gabon Sudan Tanzania S.Africa FST
(n = 91) (n = 107) (n = 124) (n = 66) (n = 86) (n = 73)
aa44 S 0.88 0.79 0.60 0.68 0.42 0.32 0.170**
G 0.12 0.21 0.40 0.32 0.58 0.68
block 2 MAD-like 0.33 0.29 0.37 0.33 0.26 0.27 0.008
K1-like 0.51 0.52 0.54 0.36 0.53 0.59
RO33-like 0.16 0.19 0.09 0.30 0.21 0.14
aa160 Q 0.29 0.38 0.27 0.48 0.31 0.21 0.024*
R 0.71 0.62 0.73 0.52 0.69 0.79
aa222 A 0.22 0.22 0.12 0.00 0.02 0.01 0.086**
V 0.78 0.78 0.88 1.00 0.98 0.99
aa297 D 0.06 0.06 0.09 0.26 0.09 0.08 0.041**
T 0.94 0.94 0.91 0.74 0.91 0.92
aa320 E 0.73 0.57 0.68 0.44 0.76 0.64 0.040**
Q 0.27 0.43 0.32 0.56 0.24 0.36
block 4b MAD-like 0.24 0.30 0.24 0.49 0.14 0.15 0.058**
K1-like 0.76 0.70 0.76 0.51 0.86 0.85
block 6-16 MAD-like 0.97 0.94 0.99 0.76 0.88 0.93 0.076**
K1-like 0.03 0.06 0.01 0.24 0.12 0.07
aa1644 E 0.42 0.43 0.50 0.13 0.42 0.24 0.064**
Q 0.58 0.57 0.50 0.87 0.58 0.76
aa1700 S 0.12 0.17 0.11 0.02 0.18 0.01 0.035**
N 0.88 0.83 0.89 0.98 0.82 0.99
Loci are indicated by codon (aa; amino-acid) position in a sequence alignment 22 or by block number (following a 17-block scheme of
the gene)13. *, P < 0.01, and **, P < 0.001, compared with FST = 0.
Table 2 Allele frequencies in two Southeast Asian
populations and FST indices of inter-population variance at four
polymorphic loci within the msp1 gene of P. falciparum
Population allele frequencies
Locus Allele Thailand Vietnam FST
(n = 287) (n = 368)
block 2 MAD-like 0.65 0.64 0.000
K1-like 0.20 0.23
RO33-like 0.15 0.13
block 4a MAD-like 0.51 0.41 0.016*
K1-like 0.49 0.59
block 4b MAD-like 0.70 0.56 0.041**
K1-like 0.30 0.44
block 6-16 MAD-like 0.61 0.82 0.104**
K1-like 0.39 0.18
Loci are indicated by block number, following a 17-block scheme of the gene13.
*, P < 0.05, and **, P < 0.001, compared with FST = 0.


































P. falciparum populations and DNA samples. Human subjects with P. falci-
parum infections were identified in studies on the epidemiology of malaria in
six geographical locations in Africa and in two locations in Southeast Asia.
The African P. falciparum isolates were those previously collected16 from
Basse in Upper River District, The Gambia, 1995 (n (number of isolates) =
91); Ibadan in Oyo state, south-western Nigeria, 1996 (n = 107); Lambarene
District in Gabon, 1996 (n = 124); Daraweesh in Gedaref state, eastern
Sudan, 1992-1995 (n = 66); Muheza District in Tanzania, 1995 (n = 86); and
KwaZulu-Natal in South Africa, 1996 (n = 73). The Southeast Asian isolates
were collected from Mae Sot in Thailand, 1996 (n = 184) (ref. 20); and Bao
Loc in Vietnam, 1994 and 1996 (n = 210) (ref. 15). Peripheral blood samples
were collected with permission and under guidelines of the relevant govern-
ment and institutional ethical committees, and DNA was isolated using stan-
dard proteinase K digestion and phenol:chloroform extraction methods.
Genotyping of allelic sequences in msp1. Ten intragenic loci in the msp1
gene were genotyped in the African samples, using PCR and sequence-spe-
cific oligonucleotide probing as described16. Natural P. falciparum infections
commonly have multiple clones and may therefore contain more than one
haploid parasite genotype34, so for each locus the single or the most abun-
dant allele in each isolate (that giving the strongest hybridization signal)
was included in a sample of allele frequency in the local population. On the
rare occasions on which different alleles were apparently equally abundant
in an isolate, a random number table was used to determine which allele
was to be sampled statistically. Thus, the sample size of alleles was equal to
the number of isolates (n = 547). Four intragenic loci in the msp1 gene were
genotyped in the Southeast Asian samples, using PCR with sequence-spe-
cific internal primers15,20,35. In accordance with the previous use of this
method, every allele found in an isolate was included in overall frequencies
in each population, so the number of alleles sampled (n = 655) in Southeast
Asia was greater than the number of isolates collected.
Genotyping of microsatellites. Nine P. falciparum microsatellite loci were
genotyped (ta1, ta42, ta81, ta87, ta109, PfPK2, G377, Polya and ARA2)18
using a semi-nested PCR method19, with some modifications in the choice
of fluorescent dye used to label the internal primer for some loci. Alleles
were identified by size after electrophoresis on an ABI 377 using GENES-
CAN and GENOTYPER software (Applied Biosystems, Warrington,
Cheshire, UK). For each locus in each isolate, a single allele (that is, the
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pared with 145 (60.9%) of the 238
individuals who did not have anti-
bodies against either (a relative risk
of 0.35, with 95% confidence inter-
val of 0.18–0.68). This gave an esti-
mated protective efficacy of 65%,
which is extremely significant (P =
0.0004 after correcting for individu-
als’ ages in years; P = 0.00002 with-
out correction).
Antibodies against the rarest of
the block 2 types (RO33-like, with
an allele frequency of 0.16) were not
significantly associated with protec-
tion (relative risk, 0.94). This weaker
non-significant effect is expected
from its low allele frequency, even if
such antibodies do offer type-spe-
cific protection. The protective ef-
fect of type-specific antibodies
cannot exceed the allele frequency
of that antigenic type of P. falci-
parum in the study population, so
investigating effects of antibodies
against this type would require a
longitudinal cohort study in a popu-
lation with a higher RO33-like allele frequency. There was no
significant association between antibodies against block 1 and
protection from malaria. Block 1 is very rarely recognized by
naturally acquired antibodies in this as in another popula-
tion24, and immunization with a synthetic peptide vaccine
containing part of this sequence failed to protect against
malaria 25. Antibody positivity against block 17 (that is, the C-
terminal Msp119 fragment)10 was also not associated with pro-
tection. However, antibody levels (absorbance values) against
the Msp119 fragment were significantly associated with protec-
tion from malaria (P = 0.028 after correction for age by logistic
regression). This indicates that differences in levels of anti-
body against Msp119 considerably higher than the cut-off
value are important. A few other studies have indicated that
serum IgG against Msp119 is associated with protection from
malaria26–28, but another recent study failed to show an associa-
tion29. Detailed structural30 and functional analyses31 indepen-
dently support the vaccine candidacy of Msp119.
In conclusion, we have predicted here which polymorphic re-
gion of a malaria parasite antigen is most likely to be a target of
acquired immunity in endemic populations, and then showed
that antibody responses to this region are strongly associated
with protection from malaria. This demonstrates that molecular
population genetic analysis can identify regions of pathogen
genes under selection, and is an effective approach to discover
targets of protective immunity to endemic pathogens. Other
population genetic approaches to identifying malaria parasite
loci under immune selection have been suggested, but not yet
tested32,33. We have identified block 2 of Msp1 as a principal can-
didate for a P. falciparum vaccine. The vaccine should incorpo-
rate the main allelic types of block 2 to induce broad, though
essentially type-specific, immunity against merozoites. Studies
are underway to identify epitopes on the different block 2 types
recognized by human antibodies, and to develop recombinant
proteins suitable for testing the efficacy of vaccination in pri-
mate models and human volunteers.
Table 3 Proportions of Gambian children acquiring clinical malaria (July–November) in
groups with or without serum IgG against the indicated regions of Msp1 in June
Percentages and numbers acquiring clinical malaria of the cohort
of 337 children grouped according to IgG reactivities in June against:
Msp1
recombinant
antigen IgG positive IgG negative RR (95% CI)a ¶ P value
K1-like Block 2
3D7 37.8% (28/74) 59.3% (156/263) 0.64 (0.47–0.87) 0.0010***
Palo Alto 40.0% (34/85) 59.9% (151/252) 0.67 (0.51–0.89) 0.0018**
DWK1#1 37.3% (22/59) 58.3% (162/278) 0.64 (0.45–0.90) 0.0033**
DWK1#2 37.3% (19/51) 57.7% (165/286) 0.65 (0.45–0.93) 0.0069**
MAD-like Block 2
Wellcome 32.7% (19/58) 60.2% (168/279) 0.54 (0.36–0.79) 0.0001***
MAD20 45.1% (37/82) 57.6% (147/255) 0.78 (0.60–1.02) 0.048*
DWMAD20 34.7% (17/49) 58.0% (167/288) 0.60 (0.40–0.89) 0.0025**
RO33-like Block 2
RO33 51.9% (27/52) 55.1% (157/285) 0.94 (0.71–1.25) 0.67
DWRO33 52.2% (48/92) 55.5% (136/245) 0.94 (0.75–1.18) 0.58
Block 1 54.5% (6/11) 54.6% (178/326) 1.00 (0.58–1.73) 1.0
Block 17 51.7% (109/211) 59.5% (75/126) 0.87 (0.71–1.05) 0.16
*, P < 0.05; **, P < 0.01; ***, P < 0.001: All of these protective associations except two (for DWK1#2 and MAD20) remain
statistically significant after adjusting for individuals’ ages in years by multiple logistic regression analysis. aRelative risks
(with 95% confidence intervals).
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only allele detected, or the most abundant allele in isolates containing
more than one genotype of P. falciparum) was counted for statistical analy-
sis of allele frequencies.
Immuno-epidemiology study cohort. Children (n = 337) 3–7 years old
(42% female), living in a rural community near Basse in the Upper River
Division of The Gambia (with intense, very seasonal malaria transmission),
were recruited for a study of immune responses and surveillance of malaria
incidence. After informed consent was obtained, 10 ml venous blood was
collected from each child at the end of June 1996, before the malaria trans-
mission season. The children were then actively monitored throughout the
transmission season (July–November) for incidence of clinical malaria. The
main measured outcome of clinical malaria in this population was a para-
sitemia of more than 5,000 P. falciparum parasites per µl blood, coincident
with an axillary temperature of more than 37.5 °C.
Recombinant Msp1 antigens and antibody assays. Block 1 (MAD20 se-
quence), block 2 (3D7, Palo Alto, DW K1#1, DWK1#2, MAD20, Wellcome,
DWMAD20, RO33 and DWRO33) and block 17 (Msp119 Wellcome se-
quence) proteins were expressed in E. coli as recombinant proteins fused to
the C terminus of glutathione S-transferase of Schistosoma japonicum using
pGEX vectors, as described23,24,36,37. Human sera were tested by enzyme-
linked immunosorbent assay (ELISA) at a dilution of 1:500 for the presence
of IgG antibodies recognizing these recombinant proteins, as described23,24.
Cut-off values above which binding of antibody was regarded as positive
were calculated as the mean + 3 s.d. of readings obtained with negative
control sera from 15 healthy Scottish blood donors.
Statistical analyses. Encoded genotypic data were imported into EXCEL
and SPSS 8.0 for analysis and tabulation of allele frequencies in each of the
geographical populations. For each locus, the inter-population variance in
allele frequencies, FST, among the six populations in Africa or between the
two populations in Southeast Asia, was calculated using Weir &
Cockerham’s θ estimator17, with the FSTAT program (version 1.2) .
Antibody ELISA results were imported into an EXCEL worksheet by investi-
gators ‘blinded’ to the epidemiological data (kept separately on a STATA
file). Data files were merged, and were analyzed independently by two in-
vestigators using EPI-INFO version 6 and SPSS 8.0 for univariate and multi-
variate (logistic regression) analyses of the predictive effects of specific
antibodies on malaria incidence.
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